Clinical Trials

Esophageal Squamous Cell Carcinoma

NCT06109207 2024-07-23

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

Phase 1 Recruiting

6 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05031949 2023-12-19

CCGLC-003

Carcinoma, Hepatocellular

NCT04393506 2023-11-22

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

21 enrolled

Mouth Neoplasms

NCT06121557 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1 Recruiting

24 enrolled

Breast

Breast Neoplasms

NCT03871855 2023-06-05

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Phase 1 Terminated

8 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT02721589 2023-02-28

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

126 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

99 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

31 enrolled

Other solid neoplasm

Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03121716 2022-07-12

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

23 enrolled

Nasopharyngeal Carcinoma

NCT05019534 2022-05-19

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

12 enrolled

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

NCT04932187 2021-09-17

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05001412 2021-08-12

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

36 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT04508686 2021-01-29

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Gynecologic

Advanced Cervical Cancer

NCT04625894 2020-11-12

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer

21 enrolled

Oligometastatic Gastrointestinal Cancer

NCT04510818 2020-08-14

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

Head and Neck Neoplasms

NCT02492789 2019-09-30

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Other hematologic neoplasm

49 enrolled

Hematologic Neoplasms

NCT03393416 2019-08-29

A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

28 enrolled

Advanced Gastric Cancer

NCT03527251 2018-05-30

SEQUENCE